MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran
pharmaphorum
JUNE 8, 2022
The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport ‘, a designation designed to speed up NHS access to promising new medicines.
Let's personalize your content